Drug
Tazemetostat
Tazemetostat: highest development phase Phase 2, developed by Eisai, Hutchmed, Ipsen. 5 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Eisai, Hutchmed, Ipsen
Trials
| Drug | Phase | Indication |
|---|---|---|
| tazemetostat NCT05713110 | Phase 2 | Relapsed/Refractory Lymphoma |
| Tazemetostat NCT05205252 | Phase 1/2 | Relapsed Hematologic Malignancy |
| Tazemetostat NCT02875548 | Phase 1/2 | Diffuse Large B-cell Lymphoma (DLBCL) |
| Tazemetostat NCT03009344 | Phase 1 | Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma |
| Tazemetostat NCT02601937 | Phase 1 | Rhabdoid Tumors |
Latest
No recent events.
Follow Tazemetostat on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.